HDAC9 and neoplasm: Synergistic interactions with HDAC inhibitors, BET inhibitors, immune checkpoint inhibitors, and DNA damage response agents have been reported in multiple preclinical and early-phase clinical studies, offering a multi-pronged approach to reverse epigenetic silencing, overcome drug resistance, and enhance anti-tumor immunity [29, 44].